Immunotherapy shares spring to life

Allogene Therapeutics describes what it is doing as "The next revolution in cell therapy." In more detail they describe themselves as "a clinical stage biotechnology company leading the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies for cancer."

Below are quotes from a recent market report describing a sharp jump in the Allogene share price.